Skip to main content

3D Medicines Approved to Launch Anti-PD-L1 in China

3D Medicines reported that China 's NMPA approved the launch of its anti-PD-L1 therapy, the first subcutaneously administered anti-PD-L1 approved anywhere in the world. Envafolimab, a novel single-domain antibody against PD-L1, is approved as a second line therapy for MSI-H/dMMR cancer in patients with advanced solid tumors. Alphamab Oncology originally discovered the drug, and 3D Medicines became its partner, with both companies responsible for clinical development. Tracon Pharma shares US rights to envafolimab with the two  China  biopharmas while Simcere will commercialize envafolimab in  China . More details... Stock Symbols: (HK: 9966) (NSDQ: TCON) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.